Combining antiplatelet and thrombolytic therapies for stroke

Expert Opinion on Pharmacotherapy
Martin M Bednar

Abstract

Pharmacological therapy for acute nonhaemorrhagic stroke has become a reality over the last 5 years. Mechanistically, both thrombolytic (tissue plasminogen activator and urokinase) and antiplatelet (aspirin) monotherapy have demonstrated efficacy. However, unintended actions limit the extent of clinical improvement in each circumstance. For example, in addition to excess bleeding, tissue plasminogen activator therapy has been associated with complement activation, neuronal toxicity and laminin degradation, while aspirin may reduce nitric oxide synthase activity and cerebral blood flow. Attention is now directed toward improving the therapeutic index for each class of agents. Generally, while thrombolytic therapy is focused on developing agents with greater fibrin specificity and safety (that is, a reduction in intracranial haemorrhage rate), the development of antiplatelet agents is primarily focused on achieving greater potency. The latter is being investigated by combining agents with different mechanisms (aspirin and dipyridamole, aspirin and clopidogrel) as well as agents designed to block the glycoprotein IIb/IIIa receptor, the final common pathway for platelet aggregation. Thus, combination therapy using both thrombolytic...Continue Reading

References

Jul 1, 1991·Stroke; a Journal of Cerebral Circulation·W M ClarkJ A Zivin
Mar 1, 1991·Stroke; a Journal of Cerebral Circulation·E MorikawaR Busto
Mar 1, 1987·Stroke; a Journal of Cerebral Circulation·C Y HsuF M Yatsu
Dec 14, 1995·The New England Journal of Medicine·UNKNOWN National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
Mar 1, 1997·Trends in Neurosciences·C Iadecola
Mar 5, 1997·European Journal of Pharmacology·S KakuM Nakashima
Jan 15, 1998·Neurological Research·M M BednarM Lynn
Dec 16, 1998·JAMA : the Journal of the American Medical Association·J HeM J Klag
Apr 3, 1999·Stroke; a Journal of Cerebral Circulation·M M Bednar, C E Gross
Jun 29, 1999·British Journal of Pharmacology·S ParmentierM Plotkine
Mar 4, 2000·Stroke; a Journal of Cerebral Circulation·UNKNOWN Abciximab in Ischemic Stroke Investigators
Mar 11, 2000·BMJ : British Medical Journal·G Gubitz, P Sandercock
Jul 14, 2000·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·K I KawanoK Umemura
Oct 13, 2000·Archives of Neurology·J A Hinchey, C Benesch
Nov 4, 2000·Expert Opinion on Investigational Drugs·M M Bednar
Feb 15, 2001·Neuroepidemiology·Z VokóM M Breteler
Feb 15, 2001·Annals of Emergency Medicine·C Lewandowski, W Barsan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

Rinshō shinkeigaku = Clinical neurology
E Mori
La Ricerca in Clinica E in Laboratorio
P M Mannucci
Ultraschall in der Medizin : Organ der Deutschen Gesellschaft für Ultraschall in der Medizin, [der] Österreichischen Gesellschaft für Ultraschall in der Medizin, [der] Schweizerischen Gesellschaft für Ultraschall in Medizin und Biologie
A van Baalen, H Versmold
© 2022 Meta ULC. All rights reserved